Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment
News: Preliminary data indicate COVID-19 vaccines remain effective against severe disease and hospitalisation caused by the Omicron variant (new)
Last updated: 11/01/2022
News: EMA receives application for conditional marketing authorisation for Paxlovid (PF-07321332 and ritonavir) for treating patients with COVID-19 (new)
CHMP, PRAC, Last updated: 10/01/2022
European Centre for Disease Prevention and Control
Weekly epidemiological update: Omicron variant of concern (VOC) – week 2 (data as of 13 January 2022) EU/EEA
Epidemiological update – 14 Jan 2022
From 20 December 2021 to 2 January 2022, there were 21 EU/EEA countries with adequate sequencing volume that reported an estimated prevalence of Omicron VOC of 46%. COVID-19 case notification and hospital admission rates were high and increasing in most countries, while death and ICU admission rates remained stable. There is still limited evidence suggesting that the observed severity associated with Omicron VOC is lower than that associated with the Delta variant. Early studies suggest that current vaccines may be less effective against Omicron infection, although they still provide protection against hospitalisation and severe disease. Given the exponential growth advantage of Omicron VOC and the high numbers of cases, any potential benefits from a lower observed severity will be short-lived and outpaced by the sheer number of severe outcomes over time.
No new digest content identified.